# Precision BioSciences, Inc. (DTIL)

> Source: Nexqual · https://nexqual.com/DTIL · data as of 2026-11-09 21:00 UTC · cite as "Nexqual, Precision BioSciences, Inc. (DTIL), nexqual.com/DTIL" · informational, not investment advice.

## What changed for DTIL since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 9, 2026).

- Precision BioSciences, Inc. (DTIL) stock went from USD 4.9 (close of the week of Aug 25, 2025, split-adjusted) to USD 9.68, a +97.6% price change; the S&P 500 (SPY) moved +18.3% over the same period.
- DTIL revenue over the last four reported quarters (through Sep 30, 2026) was $45.0M, -34.4% vs $68.7M in fiscal year 2024 (ended Dec 31, 2024), the last full year filed before September 2025; net income $7.2M → -$38.5M (SEC 10-K / 10-Q).
- Analyst actions on DTIL in the last 120 days: 1 (0 upgrades or target raises, 0 downgrades or target cuts); most recent HC Wainwright & Co., Aug 3, 2026.

**Price:** USD 9.68 (-8.68% on the day) · last close of Nov 9, 2026; US market pre market, not a live price. Prev close 10.6 · day 9.62–10.8 · 52w 3.53–11.29 · market cap $369M · NCM

## Key facts
- Last four reported quarters (through Sep 30, 2026): revenue $45.0M, net income -$38.5M (-85.6% margin), free cash flow -$51.8M (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 29.4 (range 18–60).
- Total return with dividends: 1Y +59.5% vs S&P 500 +11.7%; 5Y -96.7% vs S&P 500 +72.2%.
- Latest earnings report: 2026-11-03 (next date not yet announced).
- Dividend: DTIL paid no cash dividend in the last five years.
- Short interest: 8.66% of float (as of 2026-10-15), 8.6 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $116M | $25.1M | $48.7M | $68.7M | $34.3M | $45.0M |
| Operating income | -$39.4M | -$62.3M | -$43.7M | -$26.2M | -$52.1M | -$36.2M |
| Net income | -$30.6M | -$112M | -$61.3M | $7.2M | -$45.7M | -$38.5M |
| EPS (diluted) | -$15.60 | -$38.10 | -$15.96 | $1.04 | -$3.56 | — |
| Free cash flow | -$15.9M | -$49.1M | -$86.1M | -$58.7M | -$65.9M | -$51.8M |
| Operating margin | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% | -80.3% |
| Net margin | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% | -85.6% |
| Revenue growth | +375.7% | -78.3% | +94.1% | +41.0% | -50.1% | — |
| Cash + short-term investments | $144M | $190M | $117M | $86.3M | $116M | — |
| Total debt | $2.5M | $22.2M | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
P/S 8.2x · P/B 7.1x · FCF yield -14.02% · Earnings yield -10.43%
P/E at fiscal year-ends: Dec 2024 3.7x.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 29.4 (low 18, high 60).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | HC Wainwright & Co. | Reiterated | Buy | $60 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-10) | 5Y (from 2021-11-08) |
|---|---|---|
| Total return | +59.5% | -96.7% |
| S&P 500 (SPY) | +11.7% | +72.2% |
| Per year | +59.7% | -49.5% |
| Volatility (annualized) | 72.9% | 74.9% |
| Max drawdown | -41.2% (Nov 2025→Feb 2026) | -98.7% (Nov 2021→Feb 2026) |

## Dividends
DTIL paid no cash dividend in the last five years.

## Short interest
2,356,838 shares sold short, 8.66% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 2,223,477 shares (+6.0%). Days to cover: 8.6 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 107.1 +7.85% · ORKA (Oruka Therapeutics, Inc.) USD 104.56 +1.65% · ARWR (Arrowhead Pharmaceuticals, Inc.) USD 49.24 -15.34% · AXSM (Axsome Therapeutics, Inc.) USD 133.96 +1.20% · IMVT (Immunovant, Inc.) USD 35.15 +15.13% · CAI (Caris Life Sciences, Inc.) USD 25.57 +1.35%

## More
Full page: https://nexqual.com/DTIL · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $-0.73 | $-0.78 | +$0.04 | $0 | 3 |
| Next quarter (ends 2027-03-31) | $-0.42 | $-0.57 | +$0.15 | $0 | 1 |
| Current fiscal year (ends 2026-12-31) | $-2.94 | $-3.38 | +$0.43 | $10.9M | 3 |
| Next fiscal year (ends 2027-12-31) | $-1.80 | $-2.14 | +$0.34 | $15.5M | 3 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Sep 30, 2026 | −$0.28 | −$0.89 | Beat +68.5% | — |
| — | Quarter ended Jun 30, 2026 | −$1.26 | −$0.69 | Miss −82.6% | — |
| — | Quarter ended Mar 31, 2026 | −$0.75 | −$0.81 | Beat +7.4% | — |
| — | Quarter ended Dec 31, 2025 | $1.01 | −$0.64 | Beat +$1.65 | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-09 | 8-K | Other material event — “As previously reported, on November 5, 2026, Precision BioSciences, Inc. (the "Company") entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share (the "Common Stock"), at a price of $7.75 per share and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its Common Stock at a price of $7.749995 per pre-funded warrant (the "Offering"). The Company expects net…” | https://www.sec.gov/Archives/edgar/data/1357874/000162828026071867/0001628280-26-071867-index.htm |
| 2026-11-06 | 8-K | Other material event — “On November 5, 2026, Precision BioSciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the "Underwriters"), in connection with the offering (the "Offering"), issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share (the "Common Stock"), at a price of $7.75 per share and, in lieu of Common Stock to…” | https://www.sec.gov/Archives/edgar/data/1357874/000162828026071304/0001628280-26-071304-index.htm |
| 2026-11-05 | 8-K | Regulation FD disclosure; Other material event — “On November 5, 2026, the Company issued the HBV News Release announcing a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026. This presentation includes new and updated preliminary data from the ongoing Phase 1 ELIMINATE-B study of PBGENE-HBV, the first and only in vivo gene editing therapy designed to eliminate cccDNA, the root cause of chronic hepatitis B. The PBGENE Late Breaker Abstract for this presentation was published on November 5,…” | https://www.sec.gov/Archives/edgar/data/1357874/000162828026070542/0001628280-26-070542-index.htm |
| 2026-11-03 | Schedule 13G/A | Octagon Capital Advisors LP, Octagon Investments Master Fund LP: 5.7% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1357874/000121465926013679/0001214659-26-013679-index.htm |
| 2026-11-03 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1357874/000162828026069115/0001628280-26-069115-index.htm |
| 2026-11-03 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1357874/000162828026069092/0001628280-26-069092-index.htm |
| 2026-10-27 | Schedule 13G | BlackRock, Inc.: 5.0% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1357874/000201238326003830/0002012383-26-003830-index.htm |
| 2026-08-24 | Schedule 13G/A | Weinstein Benjamin: 4.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1357874/000203380126000004/0002033801-26-000004-index.htm |
| 2026-08-24 | 8-K | Regulation FD disclosure; Other material event — “On August 24, 2026, the Company issued a press release announcing the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of DMD.” | https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/0001628280-26-058512-index.htm |
| 2026-08-06 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1357874/000162828026053837/0001628280-26-053837-index.htm |
| 2026-08-06 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/0001628280-26-053836-index.htm |
| 2026-07-29 | Schedule 13G/A | Empery Asset Management, LP, Ryan M. Lane: 5.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1357874/000091957426004663/0000919574-26-004663-index.htm |
| 2026-07-27 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1357874/000162828026049665/0001628280-26-049665-index.htm |
| 2026-07-20 | Schedule 13G | passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1357874/000090266426003172/0000902664-26-003172-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.